Poteligeo (Mogamulizumab-kpkc) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Poteligeo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory mycosis fungoides (MF) and adults with relapsed or refractory Sézary syndrome who have received at least one prior therapy. MF and Sézary syndrome are types of cutaneous lymphoma. Poteligeo is also referred to by its drug name, mogamulizumab-kpkc.

Poteligeo is used as targeted therapy for lymphoma. Poteligeo is a member of a class of drugs called monoclonal antibodies, a type of biologic. Poteligeo is believed to work by binding to cancer cells and triggering the immune system to attack them.

How do I take it?
Prescribing information states that Poteligeo is administered intravenously in cycles that vary in timing.

Poteligeo comes in the form of an injection.

Side effects
The FDA-approved label for Poteligeo lists common side effects including rash, infusion related reactions, fatigue, diarrhea, upper respiratory tract infection and musculoskeletal pain.

Rare but serious side effects listed for Poteligeo include severe skin rashes, infections, and autoimmune complications, such as inflammation of the heart, inflammation of the muscles, and inflammation of the lungs.

For more details about this treatment, visit:

Poteligeo — Kyowa Kirin

Poteligeo — Cancer.org

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in